Fully funded by 
Content independently selected
Beyond BMI, body fat distribution shows prognostic value.
The service will be operational by spring 2020.
Reflects new data for liver, pancreatic, soft tissue, and gastric cancer.
Alternative approach promises to reduce postprocedure sepsis.
No difference in 3-year gastrointestinal or genitourinary toxicities.
MRI avoids biopsy in clinically insignificant cancer, requires fewer biopsy cores.
Successful in patients resistant to checkpoint inhibitors.
ARAMIS data also show extended metastasis-free survival.
Interim analysis of the phase 3 ENZAMET trial.
No meaningful effect on toxicity, QoL.
Cohorts from the JAVELIN Renal 101 trial are investigated for an association between tumor markers and outcomes.
Findings from a meta-analysis involving 76 studies.
Nondiagnostic findings were common.
Risk pronounced for select neoplasms.
Individual patient data study from SEER, equal-access health system, and RCTs.
Active surveillance nearly tripled during 2010-2015.
Risk factors may guide decision making to optimize urinary, sexual, and bowel function.
